Log in

NASDAQ:CVM - Cel-Sci Stock Price, Forecast & News

-0.33 (-1.98 %)
(As of 02/26/2020 06:09 AM ET)
Today's Range
Now: $16.35
50-Day Range N/A
52-Week Range
Now: $16.35
Volume731,800 shs
Average Volume1.01 million shs
Market Capitalization$595.58 million
P/E RatioN/A
Dividend YieldN/A
CEL-SCI Corporation engages in the research and development of immunotherapy for the treatment of cancer and other diseases. The company's lead investigational immunotherapy is Multikine, which is under phase III clinical trial for the treatment of primary head and neck cancer. Its Ligand Epitope Antigen Presentation System, a pre-clinical patented T-cell modulation process that stimulates the human immune system to fight bacterial, viral, and parasitic infections, as well as autoimmune diseases, allergies, transplantation rejections, and cancer. The company also develops LEAPS-H1N1-DC, a product candidate for the treatment of pandemic influenza in hospitalized patients; and CEL-2000 and CEL-4000 vaccine product candidates for the treatment of rheumatoid arthritis. CEL-SCI Corporation was founded in 1983 and is headquartered in Vienna, Virginia.

Industry, Sector and Symbol

Industry Biotechnology
Current SymbolNASDAQ:CVM



Sales & Book Value

Annual SalesN/A



Market Cap$595.58 million
Next Earnings Date5/12/2020 (Estimated)

Receive CVM News and Ratings via Email

Sign-up to receive the latest news and ratings for CVM and its competitors with MarketBeat's FREE daily newsletter.

Cel-Sci (NASDAQ:CVM) Frequently Asked Questions

What is Cel-Sci's stock symbol?

Cel-Sci trades on the NASDAQ under the ticker symbol "CVM."

How were Cel-Sci's earnings last quarter?

Cel-Sci Corporation (NASDAQ:CVM) posted its quarterly earnings results on Monday, December, 16th. The company reported ($0.20) earnings per share (EPS) for the quarter, missing the Thomson Reuters' consensus estimate of ($0.09) by $0.11. The company had revenue of $0.08 million for the quarter, compared to analysts' expectations of $0.10 million. View Cel-Sci's Earnings History.

When is Cel-Sci's next earnings date?

Cel-Sci is scheduled to release their next quarterly earnings announcement on Tuesday, May 12th 2020. View Earnings Estimates for Cel-Sci.

What price target have analysts set for CVM?

1 brokerages have issued 12-month price objectives for Cel-Sci's shares. Their forecasts range from $18.00 to $18.00. On average, they anticipate Cel-Sci's stock price to reach $18.00 in the next year. This suggests a possible upside of 10.1% from the stock's current price. View Analyst Price Targets for Cel-Sci.

What is the consensus analysts' recommendation for Cel-Sci?

1 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Cel-Sci in the last year. There are currently 1 buy rating for the stock, resulting in a consensus recommendation of "Buy." View Analyst Ratings for Cel-Sci.

Has Cel-Sci been receiving favorable news coverage?

Headlines about CVM stock have trended somewhat negative on Wednesday, according to InfoTrie. The research group scores the sentiment of news coverage by monitoring more than six thousand news and blog sources in real-time. The firm ranks coverage of public companies on a scale of negative five to five, with scores nearest to five being the most favorable. Cel-Sci earned a media sentiment score of -1.4 on InfoTrie's scale. They also gave news coverage about the company a news buzz of 0.0 out of 10, indicating that recent news coverage is extremely unlikely to have an effect on the stock's share price in the next few days. View News Stories for Cel-Sci.

Who are some of Cel-Sci's key competitors?

What other stocks do shareholders of Cel-Sci own?

Based on aggregate information from My MarketBeat watchlists, some companies that other Cel-Sci investors own include Aptose Biosciences (APTO), Ardelyx (ARDX), Compugen (CGEN), Chiasma (CHMA), DURECT (DRRX), Galectin Therapeutics (GALT), Ironwood Pharmaceuticals (IRWD), Karyopharm Therapeutics (KPTI), Proteostasis Therapeutics (PTI) and R1 RCM (RCM).

Who are Cel-Sci's key executives?

Cel-Sci's management team includes the folowing people:
  • Mr. Geert R. Kersten, CEO, Principal Accounting & Financial Officer, Treasurer and Director (Age 61)
  • Ms. Patricia B. Prichep, Sr. VP of Operations & Corp. Sec. (Age 69)
  • Dr. Eyal Talor, Chief Scientific Officer (Age 64)
  • Dr. Daniel H. Zimmerman, Sr. VP of Research & Cellular Immunology (Age 79)
  • Mr. John Cipriano, Sr. VP of Regulatory Affairs (Age 78)

How do I buy shares of Cel-Sci?

Shares of CVM can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity and Charles Schwab.

What is Cel-Sci's stock price today?

One share of CVM stock can currently be purchased for approximately $16.35.

How big of a company is Cel-Sci?

Cel-Sci has a market capitalization of $595.58 million. View Additional Information About Cel-Sci.

What is Cel-Sci's official website?

The official website for Cel-Sci is http://cel-sci.com/.

How can I contact Cel-Sci?

The company can be reached via phone at 703-506-9460.

MarketBeat Community Rating for Cel-Sci (NASDAQ CVM)

Community Ranking:  3.4 out of 5 (star star star)
Outperform Votes:  11 (Vote Outperform)
Underperform Votes:  5 (Vote Underperform)
Total Votes:  16
MarketBeat's community ratings are surveys of what our community members think about Cel-Sci and other stocks. Vote "Outperform" if you believe CVM will outperform the S&P 500 over the long term. Vote "Underperform" if you believe CVM will underperform the S&P 500 over the long term. You may vote once every thirty days.
This page was last updated on 2/26/2020 by MarketBeat.com Staff

Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter.

Yahoo Gemini Pixel